10
ALL4
Novartis Pharmaceuticals Corporation1
Propeller Health4
Sosei Heptares1
Vectura LtdYear
10
ALL2
20218
2020DEALS // DEV.
10
ALL2
Deals8
DevelopmentsCountry
10
ALL4
JAPAN4
SWITZERLAND1
U.S.A1
UNITED KINGDOM10
ALL4
Inapplicable4
Novartis Pharmaceuticals Corporation1
Propeller Health1
Valeo PharmaTherapeutic Area
10
ALL10
Pulmonary/Respiratory DiseasesStudy Phase
10
ALL10
Approved FDFDeal Type
10
ALL1
Agreement1
Collaboration8
InapplicableProduct Type
10
ALL10
Other Small MoleculeDosage Form
10
ALL10
Oral Inhalation Powder in CapsuleLead Product
10
ALL10
Indacaterol AcetateTarget
10
ALL10
ADRB2Lead Product(s) : Indacaterol Acetate,Glycopyrronium Bromide
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Approved FDF
Sponsor : Novartis Pharmaceuticals Corporation
Deal Size : Inapplicable
Deal Type : Inapplicable
QVM149 Receives Regulatory Approval in Europe and Japan
Details : QVM149 combines the bronchodilation of indacaterol acetate (a LABA) and the antimuscarinic effects of glycopyrronium bromide (a LAMA) with mometasone furoate in a precise once-daily formulation, delivered via the dose-confirming Breezhaler® device.
Product Name : Enerzair Breezhaler
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 07, 2020
Lead Product(s) : Indacaterol Acetate,Glycopyrronium Bromide
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Approved FDF
Sponsor : Novartis Pharmaceuticals Corporation
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Indacaterol Acetate,Mometasone Furoate
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Approved FDF
Sponsor : Valeo Pharma
Deal Size : Undisclosed
Deal Type : Agreement
Details : Under the Agreement, Valeo will be responsible for medical and commercial activities for Enerzair® Breezhaler® and Atectura® Breezhaler® for an initial 8 year period.
Product Name : Enerzair Breezhaler
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
March 29, 2021
Lead Product(s) : Indacaterol Acetate,Mometasone Furoate
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Approved FDF
Sponsor : Valeo Pharma
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Indacaterol Acetate,Glycopyrronium Bromide
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : New post hoc analysis results from the phase III IRIDIUM study that suggests that using Enerzair Breezhaler as a step-up therapy from medium-dose LABA/ICS provides benefit beyond increasing ICS dose alone.
Product Name : Enerzair Breezhaler
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 09, 2021
Lead Product(s) : Indacaterol Acetate,Glycopyrronium Bromide
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Indacaterol Acetate,Glycopyrronium Bromide
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Approved FDF
Sponsor : Novartis Pharmaceuticals Corporation
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Patients using Enerzair® and Atectura® Breezhaler® to manage their uncontrolled asthma in Japan will have the option to enroll in Propeller’s digital health platform to help manage their condition.
Product Name : Enerzair Breezhaler
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
August 26, 2020
Lead Product(s) : Indacaterol Acetate,Glycopyrronium Bromide
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Approved FDF
Sponsor : Novartis Pharmaceuticals Corporation
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Indacaterol Acetate,Glycopyrronium Bromide
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : High-dose, once-daily Enerzair® Breezhaler® [IND/GLY/MF] reduced asthma exacerbation rates by 21% (moderate or severe) and 31% (severe) versus medium-dose, over 52 weeks.
Product Name : Enerzair Breezhaler
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 09, 2020
Lead Product(s) : Indacaterol Acetate,Glycopyrronium Bromide
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Indacaterol Acetate,Glycopyrrolate
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : European Commission approves once-daily Enerzair® Breezhaler® in the EU, the first-in-class LABA/LAMA/ICS fixed-dose combination for patients whose asthma is uncontrolled with LABA/ICS1.
Product Name : Enerzair Breezhaler
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 07, 2020
Lead Product(s) : Indacaterol Acetate,Glycopyrrolate
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Indacaterol Acetate,Glycopyrronium Bromide
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Approved FDF
Sponsor : Novartis Pharmaceuticals Corporation
Deal Size : Inapplicable
Deal Type : Inapplicable
Sosei Heptares Notes Enerzair® Approval in Japan
Details : For the first time in Japan, a new digital device combining a sensor with the Breezhaler® inhaler is being made available. Announcement by Novartis Pharma K. K. highlights key milestone for once-daily Enerzair® (IND/GLY/MF) complete with new sensor-ena...
Product Name : Enerzair Breezhaler
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 29, 2020
Lead Product(s) : Indacaterol Acetate,Glycopyrronium Bromide
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Approved FDF
Sponsor : Novartis Pharmaceuticals Corporation
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Indacaterol Acetate,Glycopyrrolate
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase III
Sponsor : Novartis Pharmaceuticals Corporation
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Once-daily Enerzair® Breezhaler® (QVM149; IND/GLY/MF) met primary endpoint, demonstrating non-inferiority to a free combination of twice-daily Sal/Flu plus once-daily Tio in improving quality of life in people with uncontrolled asthma.
Product Name : Enerzair Breezhaler
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 06, 2020
Lead Product(s) : Indacaterol Acetate,Glycopyrrolate
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase III
Sponsor : Novartis Pharmaceuticals Corporation
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Indacaterol Acetate,Glycopyrrolate
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : If the EC follows this recommendation and approves Enerzair® Breezhaler®, it will become the first LABA/long-acting muscarinic antagonist (LAMA)/ICS fixed-dose combination for uncontrolled asthma patients.
Product Name : Enerzair Breezhaler
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 05, 2020
Lead Product(s) : Indacaterol Acetate,Glycopyrrolate
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Indacaterol Acetate,Glycopyrronium Bromide
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase III
Sponsor : Propeller Health
Deal Size : Inapplicable
Deal Type : Inapplicable
Novartis’ asthma triple heads CHMP’s latest meeting
Details : Decision supported by robust efficacy and safety data from Phase III IRIDIUM study, in which once-daily Enerzair® Breezhaler® resulted in statistically significant improvements in lung function.
Product Name : Enerzair Breezhaler
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 05, 2020
Lead Product(s) : Indacaterol Acetate,Glycopyrronium Bromide
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase III
Sponsor : Propeller Health
Deal Size : Inapplicable
Deal Type : Inapplicable